Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Fusco MJ, Casak SJ, Mushti SL, Cheng J, Christmas BJ, Thompson MD, Fu W, Wang H, Yoon M, Yang Y, Moore JN, Bi Y, Nan Y, Long CE, Auth D, Rahman NA, Tang S, Pazdur R, Fashoyin-Aje LA, Kluetz PG, Lemery SJ. Fusco MJ, et al. Among authors: fashoyin aje la. Clin Cancer Res. 2024 May 29. doi: 10.1158/1078-0432.CCR-24-0281. Online ahead of print. Clin Cancer Res. 2024. PMID: 38809262
Remote Monitoring and Data Collection for Decentralized Clinical Trials.
Daly B, Brawley OW, Gospodarowicz MK, Olopade OI, Fashoyin-Aje L, Smart VW, Chang IF, Tendler CL, Kim G, Fuchs CS, Beg MS, Zhang L, Legos JJ, Duran CO, Kalidas C, Qian J, Finnegan J, Pilarski P, Keane H, Shen J, Silverstein A, Wu YL, Pazdur R, Li BT. Daly B, et al. Among authors: fashoyin aje l. JAMA Netw Open. 2024 Apr 1;7(4):e246228. doi: 10.1001/jamanetworkopen.2024.6228. JAMA Netw Open. 2024. PMID: 38607626 Free PMC article.
Challenges and Solutions to Support Oncology Professionals Serving Underserved Populations With Cancer in the United States: Results From the ASCO Serving the Underserved Task Force.
Patel MI, Hinyard L, Merrill JK, Smith KT, Lei J, Carrizosa D, Kamaraju S, Hlubocky FJ, Kalwar T, Fashoyin-Aje L, Gomez SL, Jeames S, Florez N, Kircher SM, Tap WD. Patel MI, et al. Among authors: fashoyin aje l. JCO Oncol Pract. 2024 May;20(5):688-698. doi: 10.1200/OP.23.00595. Epub 2024 Feb 14. JCO Oncol Pract. 2024. PMID: 38354324
Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.
Donaldson JM, Seddiq M, Fusco MJ, Singla S, Pamuk GE, Lee-Alonso RJ, Mixter BD, Goldberg KB, Amiri-Kordestani L, de Claro RA, Drezner N, Gormley NJ, Kanapuru B, Lemery SJ, Fashoyin-Aje LA, Richardson NC, Singh H, Suzman DL, Theoret MR, Kluetz PG, Pazdur R. Donaldson JM, et al. Among authors: fashoyin aje la. Cancer Discov. 2023 Dec 12;13(12):2515-2524. doi: 10.1158/2159-8290.CD-23-1226. Cancer Discov. 2023. PMID: 38084090
Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges.
Fashoyin-Aje LA, Tendler C, Lavery B, Ghiorghiu S, Gerald B, Kalidas C, Richie N, Winson K, Warren NJH, Tellman TV, Retzlaff J, Foti M, Pazdur R. Fashoyin-Aje LA, et al. Clin Cancer Res. 2023 Sep 15;29(18):3566-3572. doi: 10.1158/1078-0432.CCR-23-1391. Clin Cancer Res. 2023. PMID: 37378578 Free PMC article.
56 results